company background image
A950

Access Bio KOSDAQ:A950130 Stock Report

Last Price

₩16.80k

Market Cap

₩594.6b

7D

-4.8%

1Y

-24.3%

Updated

24 May, 2022

Data

Company Financials
A950130 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends0/6

A950130 Stock Overview

Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.

Access Bio Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Access Bio
Historical stock prices
Current Share Price₩16,800.00
52 Week High₩37,350.00
52 Week Low₩14,350.00
Beta0.33
1 Month Change10.53%
3 Month Change1.21%
1 Year Change-24.32%
3 Year Change362.81%
5 Year Change253.68%
Change since IPO62.32%

Recent News & Updates

Shareholder Returns

A950130KR Medical EquipmentKR Market
7D-4.8%0.8%1.2%
1Y-24.3%-4.7%-14.3%

Return vs Industry: A950130 underperformed the KR Medical Equipment industry which returned -4.7% over the past year.

Return vs Market: A950130 underperformed the KR Market which returned -14.3% over the past year.

Price Volatility

Is A950130's price volatile compared to industry and market?
A950130 volatility
A950130 Average Weekly Movement6.6%
Medical Equipment Industry Average Movement5.6%
Market Average Movement5.4%
10% most volatile stocks in KR Market10.2%
10% least volatile stocks in KR Market3.1%

Stable Share Price: A950130 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: A950130's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200295Young-Ho Choihttps://www.accessbiodiagnostics.net

Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company was founded in 2002 and is headquartered in Somerset, New Jersey.

Access Bio Fundamentals Summary

How do Access Bio's earnings and revenue compare to its market cap?
A950130 fundamental statistics
Market Cap₩594.56b
Earnings (TTM)₩350.06b
Revenue (TTM)₩1.09t

1.7x

P/E Ratio

0.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A950130 income statement (TTM)
Revenue₩1.09t
Cost of Revenue₩246.42b
Gross Profit₩839.05b
Other Expenses₩488.99b
Earnings₩350.06b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)9.89k
Gross Margin77.30%
Net Profit Margin32.25%
Debt/Equity Ratio10.0%

How did A950130 perform over the long term?

See historical performance and comparison

Valuation

Is Access Bio undervalued compared to its fair value and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: A950130 (₩16800) is trading below our estimate of fair value (₩4381422.81)

Significantly Below Fair Value: A950130 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: A950130 is good value based on its Price-To-Earnings Ratio (1.7x) compared to the KR Medical Equipment industry average (13.6x).

PE vs Market: A950130 is good value based on its Price-To-Earnings Ratio (1.7x) compared to the KR market (14.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A950130's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: A950130 is good value based on its Price-To-Book Ratio (1x) compared to the KR Medical Equipment industry average (2.4x).


Future Growth

How is Access Bio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


4.7%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Access Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Access Bio performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


82.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A950130 has high quality earnings.

Growing Profit Margin: A950130's current net profit margins (32.2%) are lower than last year (50.8%).


Past Earnings Growth Analysis

Earnings Trend: A950130 has become profitable over the past 5 years, growing earnings by 82.3% per year.

Accelerating Growth: A950130's earnings growth over the past year (104.5%) exceeds its 5-year average (82.3% per year).

Earnings vs Industry: A950130 earnings growth over the past year (104.5%) exceeded the Medical Equipment industry 15.1%.


Return on Equity

High ROE: A950130's Return on Equity (61.1%) is considered outstanding.


Financial Health

How is Access Bio's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: A950130's short term assets (₩921.9B) exceed its short term liabilities (₩448.2B).

Long Term Liabilities: A950130's short term assets (₩921.9B) exceed its long term liabilities (₩41.7B).


Debt to Equity History and Analysis

Debt Level: A950130 has more cash than its total debt.

Reducing Debt: A950130's debt to equity ratio has reduced from 47.2% to 10% over the past 5 years.

Debt Coverage: A950130's debt is well covered by operating cash flow (1215.7%).

Interest Coverage: A950130's interest payments on its debt are well covered by EBIT (132.9x coverage).


Balance Sheet


Dividend

What is Access Bio current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A950130's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A950130's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A950130's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A950130's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A950130 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

₩1b

CEO Compensation


CEO

Young-Ho Choi (57 yo)

no data

Tenure

₩1,253,869,869

Compensation

Mr. Young-Ho Choi serves as Chief Executive Officer and President of Access Bio, Inc. Mr. Choi has R&D and managements experience for IVD field. Mr. Choi is an Oak Ridge Conference Outstanding Awardee for...


CEO Compensation Analysis

Compensation vs Market: Young-Ho's total compensation ($USD995.23K) is about average for companies of similar size in the KR market ($USD913.39K).

Compensation vs Earnings: Insufficient data to compare Young-Ho's compensation with company performance.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Access Bio, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Access Bio, Inc.
  • Ticker: A950130
  • Exchange: KOSDAQ
  • Founded: 2002
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: ₩594.563b
  • Shares outstanding: 35.39m
  • Website: https://www.accessbiodiagnostics.net

Number of Employees


Location

  • Access Bio, Inc.
  • 65 Clyde Road
  • Suite A
  • Somerset
  • New Jersey
  • 8873
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/24 00:00
End of Day Share Price2022/05/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.